6-K
ASTRAZENECA PLC (AZN)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of March 2025
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
Director/PDMR Shareholding
5 March 2025
Transactions by Persons Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 4 March 2025, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
| PDMR | Position | Ordinary Shares granted under the AZDBP | Ordinary Shares granted under the AZPSP | Award price per Ordinary Share |
|---|---|---|---|---|
| Pascal Soriot | Executive Director and Chief Executive Officer | 14,623 | 109,781 | £119.63 |
| Aradhana Sarin | Executive Director and Chief Financial Officer | 6,243 | 45,494 | £119.63 |
The AZDBP award represents the portion of each PDMR's annual bonus for 2024 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.
The AZPSP award is subject to a combination of performance measures focused on scientific, commercial, financial and sustainability performance. The performance measures will be assessed over a three-year performance period (1 January 2025 to 31 December 2027). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2024, which is available on the Company's website at www.astrazeneca.com/annualreport2024.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
| 1 | Details of the person discharging managerial responsibilities /<br>person closely associated | |
|---|---|---|
| a) | Name | Pascal Soriot |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |
| a) | Name | AstraZeneca PLC |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 |
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | |
| a) | Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification code | Ordinary Shares of US0.25 each in AstraZeneca PLC<br><br><br> <br><br><br>GB0009895292 |
| b) | Nature of the transaction | Grants of share awards under the AstraZeneca Performance Share Plan<br>and the AstraZeneca Deferred Bonus Plan |
| c) | Price(s) and volume(s) | Price(s) |
| 119.63 | ||
| d) | Aggregated information<br><br><br><br><br><br>- Aggregated volume<br><br><br>- Price | Not applicable - single transaction |
| e) | Date of the transaction | 4 March 2025 |
| f) | Place of the transaction | Outside a trading venue |
All values are in US Dollars.
| 1 | Details of the person discharging managerial responsibilities /<br>person closely associated | |
|---|---|---|
| a) | Name | Aradhana Sarin |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |
| a) | Name | AstraZeneca PLC |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 |
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | |
| a) | Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification code | Ordinary Shares of US0.25 each in AstraZeneca PLC<br><br><br> <br><br><br>GB0009895292 |
| b) | Nature of the transaction | Grants of share awards under the AstraZeneca Performance Share Plan<br>and the AstraZeneca Deferred Bonus Plan |
| c) | Price(s) and volume(s) | Price(s) |
| 119.63 | ||
| d) | Aggregated information<br><br><br><br><br><br>- Aggregated volume<br><br><br>- Price | Not applicable - single transaction |
| e) | Date of the transaction | 4 March 2025 |
| f) | Place of the transaction | Outside a trading venue |
All values are in US Dollars.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AstraZeneca<br>PLC |
|---|
Date: 05 March 2025
| By: /s/<br>Adrian Kemp |
|---|
| Name:<br>Adrian Kemp |
| Title:<br>Company Secretary |